
    
      By comparing values measured at different timepoints, the study is expected to provide
      insight regarding the ability of 6R-BH4, administered along with their currently prescribed
      antihypertension medications, to improve endothelial function, reduce SBP, and reduce
      arterial stiffness in patients with ISH and endothelial dysfunction
    
  